Australia's CSL is wielding the axe, cutting its workforce by 15% – around 3,000 positions – while announcing plans to spin its vaccines unit into a standalone company. The decision to demerge the CSL ...

CSL Ltd., the world’s second-biggest maker of flu shots, forecast a US vaccination rebound as health groups counter misinformation and rising illness rates revive concern about prevention. A recovery ...

CSL showcases Seqirus revenue growth and market leadership at its 2025 Capital Markets Day in Chicago. CSL's Seqirus division has grown revenue from $751 million in FY16 to a projected $2 billion in ...

US vaccination forecast leads to fall in stock price, while board survives spill in ‘second strike’ over pay concerns at AGM Follow our Australia news live blog for latest updates Get our breaking ...

SYDNEY, Oct 28 (Reuters) - Australian biotech CSL (CSL.AX), opens new tab has cut its profit outlook and delayed plans to spin off its vaccine division, blaming an unprecedented fall in U.S. flu ...

A strike is when more than 25 per cent of shareholders are against a company proposal, in this case executive pay, paving the way for a second ballot on whether to spill the board. Shareholders have ...

CSL Ltd. plunged to the lowest in almost seven years after Australia’s biggest drugmaker postponed plans to spin off its vaccines business, as falling US flu immunizations deepen concern over a ...

CSL (ASX:CSL) has attracted fresh attention after its Broadmeadows plasma fractionation facility in Australia was named the Overall Winner of the 2025 Facility of the Year Award by the International ...

A rare 2023 BMW M4 CSL with only 1,600 miles is up for sale on Bring a Trailer. This lightweight, high-performance coupe looks almost new and demands attention. The Ultimate Driving Machine never ...

Gift 5 articles to anyone you choose each month when you subscribe. CSL chief financial officer Joy Linton retired on Tuesday. That’s the big Australian biotech trying to change the story. Something ...

CSL will invest up to $760 million in Dutch biotech VarmX, marking the healthcare giant’s first major investment since it announced 3000 job cuts and plans to scale back its global research and ...

Nearly 15 per cent of CSL’s global workforce will be reduced in the biggest shake-up of the company in decades aimed at “simplifying the business”. CSL employs about 30,000 staff globally. Its share ...